• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助放疗食管鳞癌靶区定义:中国专家的多中心推荐意见。

Neoadjuvant radiation target volume definition in esophageal squamous cell cancer: a multicenter recommendations from Chinese experts.

机构信息

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, No. 440, Jiyan Road, Huaiyin distract, Jinan, 250117, Shandong Province, China.

Department of Oncology, Yankuang New Journey General Hospital, Zoucheng, 273500, China.

出版信息

BMC Cancer. 2024 Sep 2;24(1):1086. doi: 10.1186/s12885-024-12825-2.

DOI:10.1186/s12885-024-12825-2
PMID:39223503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11367793/
Abstract

BACKGROUND

This study aimed to establish a consensus on the delineation of target volumes for neoadjuvant radiation therapy (nRT) in esophageal squamous cell carcinoma (ESCC) within China.

METHODS

From February 2020 to June 2021, nine ESCC patients who received nRT were retrospectively selected from Sun Yat-sen University Cancer Center and Shandong Cancer Hospital. A panel from eight cancer radiotherapy centers performed two rounds of nRT target volume delineation for these patients: the first round for cases 1-6 and the second for cases 7-9. Online meetings were held after each delineation round to discuss findings. The consistency of delineations across centers was compared using mean undirected Hausdorff distances (Hmean), dice similarity coefficients (DSC), and total volumes, analyzed with the Mann-Whitney U test.

RESULTS

The second round of delineations showed improved consistency across centers (total clinical target volume (CTVtotal): mean DSC = 0.76-0.81; mean Hmean = 2.11-3.14 cm) compared to the first round (CTVtotal: mean DSC = 0.63-0.64; mean Hmean = 5.66-7.34 cm; DSC and Hmean: P < 0.050 between rounds), leading to the formation of a consensus and an atlas for ESCC nRT target volume delineation. A proposal was reached through evaluating target volume delineations, analyzing questionnaire survey outcomes, and reviewing pertinent literature.

CONCLUSIONS

We have developed guidelines and an atlas for target volume delineation in nRT therapy for ESCC in China. These resources are designed to facilitate more consistent delineation of target volumes in both clinical practice and clinical trials.

摘要

背景

本研究旨在建立中国范围内用于新辅助放化疗(nRT)的食管癌(ESCC)靶区勾画共识。

方法

从 2020 年 2 月至 2021 年 6 月,从中山大学肿瘤防治中心和山东省肿瘤医院回顾性选择了 9 例接受 nRT 的 ESCC 患者。来自 8 家癌症放疗中心的一个小组为这些患者进行了两轮 nRT 靶区勾画:第一轮为病例 1-6,第二轮为病例 7-9。每轮勾画后均举行在线会议讨论结果。使用无向 Hausdorff 距离(Hmean)、骰子相似系数(DSC)和总体积的平均值比较各中心勾画的一致性,采用 Mann-Whitney U 检验进行分析。

结果

与第一轮相比(CTVtotal:平均 DSC=0.63-0.64;平均 Hmean=5.66-7.34cm),第二轮各中心的勾画一致性有所提高(CTVtotal:平均 DSC=0.76-0.81;平均 Hmean=2.11-3.14cm),从而形成了 ESCC nRT 靶区勾画的共识和图谱。通过评估靶区勾画、分析问卷调查结果和回顾相关文献,提出了建议。

结论

我们制定了用于中国 ESCC 新辅助放化疗的靶区勾画指南和图谱。这些资源旨在促进在临床实践和临床试验中更一致地勾画靶区。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/260a/11367793/716ea59962d9/12885_2024_12825_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/260a/11367793/0a287c30ad90/12885_2024_12825_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/260a/11367793/d91fa20dff71/12885_2024_12825_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/260a/11367793/716ea59962d9/12885_2024_12825_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/260a/11367793/0a287c30ad90/12885_2024_12825_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/260a/11367793/d91fa20dff71/12885_2024_12825_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/260a/11367793/716ea59962d9/12885_2024_12825_Fig3_HTML.jpg

相似文献

1
Neoadjuvant radiation target volume definition in esophageal squamous cell cancer: a multicenter recommendations from Chinese experts.新辅助放疗食管鳞癌靶区定义:中国专家的多中心推荐意见。
BMC Cancer. 2024 Sep 2;24(1):1086. doi: 10.1186/s12885-024-12825-2.
2
Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer.食管癌新辅助治疗靶区勾画建议。
Radiother Oncol. 2021 Mar;156:102-112. doi: 10.1016/j.radonc.2020.11.032. Epub 2020 Dec 5.
3
Deep Learning for Automatic Gross Tumor Volumes Contouring in Esophageal Cancer Based on Contrast-Enhanced Computed Tomography Images: A Multi-Institutional Study.基于增强 CT 图像的食管癌自动大体肿瘤体积勾画的深度学习:多中心研究。
Int J Radiat Oncol Biol Phys. 2024 Aug 1;119(5):1590-1600. doi: 10.1016/j.ijrobp.2024.02.035. Epub 2024 Mar 2.
4
Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China.胸段食管癌根治性放疗中靶区勾画的观察者间变异性:来自中国的多中心研究。
Radiat Oncol. 2021 Jun 9;16(1):102. doi: 10.1186/s13014-020-01691-4.
5
Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: national guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group.早期乳腺癌辅助放疗中靶区和危及器官的勾画:丹麦乳腺癌合作组的国家指南和勾画图谱。
Acta Oncol. 2013 May;52(4):703-10. doi: 10.3109/0284186X.2013.765064. Epub 2013 Feb 19.
6
Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.放射性食管鳞癌的预后:MSKCC 经验。
J Gastrointest Surg. 2019 Jan;23(1):11-22. doi: 10.1007/s11605-018-3958-8. Epub 2018 Sep 13.
7
Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy.接受新辅助免疫治疗联合化疗的局部晚期食管鳞状细胞癌患者的放射治疗
Sci Rep. 2024 Jul 17;14(1):16495. doi: 10.1038/s41598-024-67419-6.
8
Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.新辅助化疗后残余癌体积可预测食管鳞状细胞癌患者的临床结局
Int J Surg Pathol. 2019 Oct;27(7):713-721. doi: 10.1177/1066896919855760. Epub 2019 Jun 17.
9
Diffusion-weighted MRI and F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.弥散加权 MRI 联合 F-FDG PET/CT 评估局部进展期食管鳞癌新辅助放化疗疗效
Radiat Oncol. 2021 Jul 19;16(1):132. doi: 10.1186/s13014-021-01852-z.
10
[Efficacy analysis of the radiotherapy and chemotherapy in patients with stage Ⅳ esophageal squamous carcinoma: a multicenter retrospective study of Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG R-01F)].[Ⅳ期食管鳞癌患者放化疗疗效分析:京津冀食管癌和食管胃交界癌放疗肿瘤学组(3JECROG R-01F)多中心回顾性研究]
Zhonghua Zhong Liu Za Zhi. 2020 Aug 23;42(8):676-681. doi: 10.3760/cma.j.cn112152-20190327-00197.

本文引用的文献

1
Patterns and trends in esophageal cancer incidence and mortality in China: An analysis based on cancer registry data.中国食管癌发病率和死亡率的模式与趋势:基于癌症登记数据的分析
J Natl Cancer Cent. 2023 Jan 25;3(1):21-27. doi: 10.1016/j.jncc.2023.01.002. eCollection 2023 Mar.
2
A Phase 1b Clinical Trial of Neoadjuvant Radio-immunotherapy for Esophageal Squamous Cell Cancer.一项新辅助放免疫治疗食管鳞癌的 1b 期临床试验。
Int J Radiat Oncol Biol Phys. 2024 Jul 1;119(3):896-901. doi: 10.1016/j.ijrobp.2023.12.033. Epub 2024 Jan 4.
3
A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
新辅助化疗、新辅助放化疗和新辅助免疫化疗治疗局部晚期食管鳞癌的临床病理结局和淋巴转移模式比较。
Ann Surg Oncol. 2024 Feb;31(2):860-871. doi: 10.1245/s10434-023-14534-9. Epub 2023 Nov 10.
4
Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer: comprehensive analysis for dosimetry, treatment-related complications, impact on lymphocyte, patterns of failure and survival.局部晚期食管癌新辅助放化疗中累及野照射或选择性淋巴结照射:剂量学、治疗相关并发症、对淋巴细胞的影响、失败模式及生存情况的综合分析
Front Oncol. 2023 Oct 10;13:1274924. doi: 10.3389/fonc.2023.1274924. eCollection 2023.
5
Transesophageal endoscopic ultrasound with bronchoscope-guided fine-needle aspiration for diagnostic and staging purposes: a narrative review.经食管内镜超声检查联合支气管镜引导下细针穿刺活检用于诊断和分期:一项叙述性综述
J Thorac Dis. 2023 Sep 28;15(9):5088-5098. doi: 10.21037/jtd-23-681. Epub 2023 Aug 21.
6
A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901).特瑞普利单抗联合新辅助放化疗治疗局部晚期食管鳞状细胞癌的II期临床试验(NEOCRTEC1901)
EClinicalMedicine. 2023 Jul 26;62:102118. doi: 10.1016/j.eclinm.2023.102118. eCollection 2023 Aug.
7
Role of Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) in the Diagnosis of Suspicious Malignant Esophageal Strictures.内镜超声引导下细针穿刺抽吸术(EUS-FNA)在可疑恶性食管狭窄诊断中的作用
J Clin Med. 2023 Mar 9;12(6):2153. doi: 10.3390/jcm12062153.
8
Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design.术前帕博利珠单抗联合放化疗治疗食管鳞状细胞癌:试验设计
JTCVS Open. 2021 Nov 10;9:293-299. doi: 10.1016/j.xjon.2021.11.003. eCollection 2022 Mar.
9
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.2020年食管鳞状细胞癌和食管腺癌发病率及死亡率的全球格局以及至2040年的预测:来自GLOBOCAN 2020的新估计
Gastroenterology. 2022 Sep;163(3):649-658.e2. doi: 10.1053/j.gastro.2022.05.054. Epub 2022 Jun 4.
10
Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617.III期非小细胞肺癌患者中,免疫细胞接受更高辐射剂量与更差的肿瘤控制及总生存期相关:RTOG0617的二次分析
Cancers (Basel). 2021 Dec 8;13(24):6193. doi: 10.3390/cancers13246193.